Bolt Threads leverages Ginkgo Bioworks' protein manufacturing platform

By The Science Advisory Board staff writers

August 5, 2021 -- Biotechnology company Bolt Threads has formed a partnership with Ginkgo Bioworks to leverage the company's engineering technology for the development of synthetic products for the beauty and personal care industries.

Bolt recently developed b-silk protein, a new ingredient inspired by the strength and elasticity of spider silk. The protein offers silklike softness, provides powerful skin defense, and has the potential to sustainably replace synthetic ingredients like silicone in skin and hair care products, the company reported.

Bolt Threads is collaborating with Ginkgo Bioworks to improve the sustainability, efficiency, and cost effectiveness of Bolt
Bolt Threads seeks to leverage Ginkgo's long-established expertise in strain engineering to improve the sustainability, efficiency, and cost effectiveness of its b-silk protein manufacturing process. Image courtesy of Ginkgo Bioworks.

The partnership will leverage Ginkgo's strain engineering capabilities, with the goal of improving production efficiency, Bolt representatives said.

Bolt has secured partnerships with consumer brands, including Kering, Stella McCartney, Adidas, and Lululemon, to bring advanced biological materials to consumers around the globe, the company stated. B-silk protein is currently available for purchase in premium product lines like Vegamour.

Trial and error help researchers design large 'ideal' proteins
Researchers have designed "ideal" functional proteins using a trial-and-error iterative process that combines computer design and lab experiments based...
Biogen, Ginkgo partner on enhanced AAV manufacturing for gene therapies
Biogen and Ginkgo Bioworks will collaborate to develop improved methods for manufacturing recombinant adeno-associated virus (AAV)-based vectors.
Ginkgo Bioworks nabs $1.1B to fight COVID-19 in U.S.
The U.S. International Development Finance Corporation has approved a loan of up to $1.1 billion to Ginkgo Bioworks, enabling it to expand biosecurity...
Akron, Synairgen partner on IFN-beta treatment for COVID-19
Cell therapeutics company Akron Biotechnology and respirator drug development firm Synairgen have partnered to advance interferon-beta (IFN-beta) treatment...
Totient advances anti-SARS-CoV-2 antibodies with funding, partnerships
Ginkgo Bioworks and artificial intelligence drug discovery firm Totient have partnered to identify antibodies effective against the novel coronavirus...

Copyright © 2021 scienceboard.net


Conferences
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter